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A B S T R A C T
Alpha synuclein (αS) is a ~14 kDa intrinsically disordered protein. Decades of research have increased our
knowledge on αS yet its physiological function remains largely elusive. The conversion of monomeric αS into
oligomers and amyloid ﬁbrils is believed to play a central role of the pathology of Parkinson's disease (PD). It is
becoming increasingly clear that the interactions of αS with cellular membranes are important for both αS's
functional and pathogenic actions. Therefore, understanding interactions of αS with membranes seems critical to
uncover functional or pathological mechanisms. This review summarizes our current knowledge of how phy-
sicochemical properties of phospholipid membranes aﬀect the binding and aggregation of αS species and gives
an overview of how post-translational modiﬁcations and point mutations in αS aﬀect phospholipid membrane
binding and protein aggregation. We discuss the disruptive eﬀects resulting from the interaction of αS aggregate
species with membranes and highlight current approaches and hypotheses that seek to understand the patho-
genic and/or protective role of αS in PD.
1. From generic amyloids to amyloids of alpha synuclein
1.1. A time capsule; the discovery of alpha synuclein (αS) amyloids
The term “amyloid” as used today in the biochemistry and bio-
physics community, refers to ﬁbrillar protein structures with a typical
width of 5–10 nm that have a characteristic cross β-sheet secondary
structure. Deposits of these ﬁbrils in or outside cells are also called
plaques and exhibit positive birefringence under polarized light. Less
than two centuries ago, the normal starch-like constituent in plants that
can be visualized using iodine staining was referred as amyloid [1].
Sixteen years later, intracellular deposits in brain tissues stained posi-
tively by iodine were therefore thought be carbohydrates and their
relevance to disease was believed to be circumstantial [2]. It was in
1859 when Friedreich and Kekulé showed that amyloid plaques mainly
contained proteins, that the research attention shifted to the study of
amyloids as protein aggregates [3]. Subsequently, the presence of
amyloids was thought to be a consequence of aging and disease con-
ditions including cancer and many auto-immune diseases rather than a
cause of disease.
In 1912, Friedrich Lewy described proteinaceous inclusion bodies in
neurons of patients suﬀering from Parkinson's disease (PD) [4]. These
spherical and thread like inclusions in neuronal bodies, now called
Lewy bodies (LBs) and Lewy Neurites [5], would later be recognized as
a pathological hallmark of PD.> 4 decades later, Cohen and Calkins
showed, using electron microscopy, that the proteins in these inclusions
had a characteristic ﬁbrillar ultra-structure. The dimensions of the ﬁ-
brils ranged between 5 and 12 nm in width and were referred to as
amyloid ﬁbrils [6]. Further studies showed that the protein ﬁbrils, ir-
respective of their origin, were composed of even thinner structures
which were named protoﬁbrils [7,8]. The following year, the basic
structure of the protein ﬁbrils was shown to be a β-pleated sheet [9].
We shall henceforth refer to such ﬁbrils as amyloids. Since then, nu-
merous reports, using high resolution techniques like cryo-electron
microscopy (Cryo-EM), solid state nuclear magnetic resonance
(ssNMR), magic angle spinning nuclear magnetic resonance (MAS-
NMR), x-ray ﬁber diﬀraction (XRD) and two-dimensional infra-red
spectroscopy (2D-IR), have fueled the structural understanding of the
amyloid state of numerous proteins (Fig. 1). It is now known that
amyloid formation is not a rare phenomenon associated merely with
diseases but rather it deﬁnes a structurally and thermodynamically
stable form of proteins. The amyloid ﬁbril is a low energy alternative to
the native state, which can in principle be adopted by many, if not all,
polypeptide sequences [10]. There are now about 50 known disorders
with widely disparate symptoms, each of which involve the conversion
of normally soluble and functional peptides/proteins that possess either
a distinct secondary structure or are intrinsically disordered into amy-
loid ﬁbrils [11]. If, and how, the transition to the amyloid state is a
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consequence or a cause of these diseases is still debated. Here we will
review the possible causative relation between the formation of amy-
loid aggregates of the protein alpha-synuclein (αS) and the develop-
ment of Parkinson's disease. αS is a soluble intrinsically disordered
protein (IDP) that is abundantly present in neurons. The protein is as-
sociated with intracellular membranes and membrane binding is one of
its major putative functional roles. Membranes are however also
implicated as the main target of toxic interactions. In reviewing the role
of αS aggregates in the development of PD, we will therefore focus on
the possible membrane damage caused by amyloid aggregation or ag-
gregates.
The main protein found within amyloid deposits in LBs of
Parkinson's disease patients is αS. This protein was initially found in the
synapse and in the nuclear envelope of Torpedo californica [12] in 1988.
Fig. 1. Timeline of selected events relating to αS and amyloids.
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The connection of αS to neurodegenerative disorders was not estab-
lished until the discovery of a distinct peptide component in the amy-
loid plaques in the brains of Alzheimer's disease (AD) patients [13].
This ~35 amino acid peptide component was referred to as the non-Aβ
component (NAC). The NAC was generated from the proteolytic clea-
vage of a 140 amino-acid protein called NAC precursor protein, NACP.
NACP was later shown to be a homologue of human αS [14,15]. The
NAC peptide itself turned out to be highly amyloidogenic and anti-
bodies raised against synthetic NAC peptides recognized amyloid ﬁbrils
in AD plaques [13,16]. NACP was subsequently described as a natively
unfolded protein [17] that loosely associates with synaptic vesicles
[15,18] and expresses abnormally in the presynaptic terminals of
neuronal cells of the central nervous system in patients aﬄicted with
AD [15,19] (Fig. 1).
The link between αS/NACP and PD was established in 1997, when a
point mutation (A53T)1 in the αS gene was identiﬁed in families with
autosomal dominant PD [20]. This observation was followed by the
seminal discovery of αS as the major component of LBs in brain tissues
of sporadic PD cases [21] and the positive immunostaining of these LBs
with anti-NACP antibodies [22]. The following year, it was shown that
αS was present in LBs as 5–10 nm thick ﬁbrils. In these ﬁbrils αS
monomers organized in β-strands that are oriented parallel to the ﬁ-
brillar axis [23]. These discoveries triggered tremendous scientiﬁc in-
terest in αS and the possible causality of αS aggregation and the de-
velopment of PD. The following year, reports appeared showing that
diseased related familial mutants of αS accelerated ﬁbril formation. The
accelerated formation of ﬁbrils suggested a direct link between ag-
gregation of αS and the development of early onset PD [24]. Triplica-
tion of the αS gene was also shown to cause early onset PD [25] and
mRNA levels of αS were found to be consistently elevated in brains of
both early onset familial PD [26] and idiopathic PD patients [27]. αS
amyloid deposits were also detected in several other neurodegenerative
diseases, including multiple system atrophy (MSA), amyotrophic lateral
sclerosis (ALS), dementia with Lewy bodies (DLB) and Hallervorden-
Spatz syndrome. These diseases are now collectively referred to as sy-
nucleinopathies [28]. It is worthwhile to note that often neurodegen-
erative disorders consist of a continuum of amyloid-related proteino-
pathies i.e. besides amyloid deposits of αS other amyloidogenic proteins
also accumulate amyloid aggregates [29].
1.2. Alpha-synuclein
The synuclein family consists of α-synuclein, β-synuclein, and γ-
synuclein. These small highly conserved proteins consist of an amino-
terminal domain with a variable number of 11-residue repeats, range
from 127 to 140 amino acids in length and are 55–62% identical in
sequence. Full length monomericαS is a 140 amino-acid protein. Its
sequence can be divided into three major regions: the N-terminal re-
gion, the NAC region and the C-terminal region. The N-terminal region
comprises of amino acid residues 1–60 and can organize into a mem-
brane binding amphipathic helix. The hydrophobic NAC region com-
prises residues 61–94 and can organize into cross β-sheets. The NAC
region is therefore required for aggregation into amyloid ﬁbrils. Part of
the NAC region is also involved in membrane binding and seems to
deﬁne the aﬃnity of αS for lipid membranes [30]. The negatively
charged C-terminal region comprises residues 95–140 and is highly
unstructured and weakly hydrophobic. It experiences weak and tran-
sient interactions, if any, with model lipid membranes [30] (Fig. 2). The
C-terminal region remains unstructured in the amyloid ﬁbril and
truncations of this region have been shown to modulate aggregation of
αS into amyloids [31–33]. The C-terminal region contains sites that can
be post-translationally modiﬁed by e.g. nitration and phosphorylation
[34–36]. Whether these modiﬁcations are related to function or result
in functional disorders is not known. It is however clear that they aﬀect
the net charge of the C-terminal region and have profound impact on
the αS aggregation and membrane binding as discussed in the later
section. β- and γ-synucleins diﬀer from α-synuclein by virtue of the
deletion of 11 amino acids in the NAC region and a shorter C-terminal
domain respectively. The β- and γ-synuclein proteins are not found in
LBs, but both are associated with hippocampal axon pathology in Par-
kinson's disease and dementia with LBs [37].
Till today, 5 additional point mutations, besides the aforementioned
A53T, in the αS gene have been identiﬁed that lead to protein variants
found in familial forms of PD:A30P [38], E46K [39], A53E [40], H50Q
[41] and G51D [42]. Interestingly, all known disease-linked point
mutations reside in the membrane binding N-terminal region of αS
suggesting that changes in the membrane interactions of monomeric αS
are relevant to PD. Although there seems a clear link between muta-
tions in αS and the onset of PD, the role of αS in the disease etiology is
constantly debated and ﬁnding the mechanism(s) responsible for cel-
lular damage in PD remains a holy grail.
In PD, αS assembles into oligomeric aggregates and amyloid ﬁbrils.
Oligomeric protein aggregates have been suggested to play a pivotal
role in PD and are often referred to as the more toxic aggregate species
responsible for cell death [43–46].Oligomeric αS was ﬁrst observed in
in vitro studies on the aggregation of recombinantly produced αS [24].
Subsequently, αS oligomers were reported to be present in postmortem
brain of patients with PD [47], cell line cultures [48–50] and neurons
[51]. High oligomer concentrations have been associated with disease,
but the toxic mechanism responsible for oligomer induced cell death is
still under debate [47,52]. The observation that diﬀerent types of oli-
gomers exist and that they possibly each contribute diﬀerently to
toxicity in PD complicates this debate [53]. The best characterized αS
oligomer species in in vitro studies appears in simple buﬀer solution
without aggregation stimulating additives such as dopamine metabo-
lites, fatty acids, or heavy metal cations (reviewed in [54]). This oli-
gomer consists of approximately 30 monomers [55–57]. The oligomer
contains some β-sheet structure [58–60], and the C-terminal region of
the protein remains ﬂexible and solvent exposed [60,61]. The β-sheet
structure of oligomeric αS species has been reported to be distinct from
that of ﬁbrils; oligomers were observed to contain antiparallel β-sheets
whereas in αS ﬁbrils monomers are typically organized parallel β-sheets
[62]. The N-terminal region of the protein in the oligomers retains some
of its membrane binding properties [63]. For many of the proposed
toxic mechanisms that involve oligomers, the ability to interact with
membranes seems to be essential. These mechanisms include mem-
brane thinning [43], pore formation [46], enhanced lipid ﬂip-ﬂop [64]
and vesicle clustering [65].
High resolution structures of αS ﬁbrils have been obtained from
micro electron diﬀraction (microED) studies on αS segments [66],
solid-state NMR studies [67–69] and more recently the atomic structure
of the N-terminally acetylated αS full length and a truncation variant
comprising of residues 1–121 was determined from Cryo-EM images
[70,71]. However, whether the Greek-key topology reported in the
aforementioned studies, is also adopted by αS in in vivo formed amyloid
ﬁbrils remains to be investigated. Structural characterization of αS
amyloid ﬁbrils that are formed in vivo or in vitro is complicated by the
existence of diﬀerent ﬁbril polymorphs and the sensitivity of the ﬁbril
structure to the aggregation conditions used [72,73]. Structural poly-
morphs of αS ﬁbrils have been shown to result in signiﬁcantly diﬀerent
toxicities in neuronal cell cultures [68,74]. A recent study has shown
that αS ﬁbrils can be internalized, bind plasma membranes of both
neuroblastoma cell lines and hippocampal primary neurons and induce
cell death when besides ﬁbrils αS monomers are present [75]. The
proposed mechanisms of amyloid ﬁbril-mediated membrane damage
include membrane deformations and lipid extraction [76] and the ac-
tivation of apoptotic cell-death pathways [75].
1 A point mutation in the human αS gene leading to production of a αS
variant in which the amino acid alanine at position 53 is substituted by
threonine due to a single nucleotide substitution.
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Not only the role of αS in PD but also the physiological function of
αS still eludes us. However, several decades of research have resulted in
important progress towards understanding its function as enumerated
in the next section. It is now known that αS is predominantly found in
the presynaptic terminals of neurons in the human brain. Lower
amounts of the protein are present in other tissues. In these cells and
tissues, the N-terminal methionine of αS is post-translationally mod-
iﬁed; αS is acetylated in its physiological monomeric state [77–79].
Although αS was reported to exist as a stable α-helical tetramer [77,80]
reports from other labs failed to conﬁrm the existence of a tetrameric
αS species [78,81]. The monomeric N-terminal acetylated form is
therefore generally believed to represent the functional form of the
protein.
αS has been reported to have many interaction partners including
cellular membranes and an enormous number of diﬀerent proteins
[82]. This led to the suggestion that αS may act as an interaction hub
for diﬀerent binding partners [83].Although we focus on (toxic)
membrane interactions in this review, the whole picture is probably
more complicated since interactions in such a putative hub are inter-
dependent e.g. the depletion of αS monomer pool by aggregation may
disrupt distribution over functional interactions. Membrane bound αS
has been suggested to play a role in regulating synaptic vesicle pools
[84], vesicle traﬃcking [85,86] and vesicle fusion events at the synapse
[87]. The mechanism by which αS regulates these processes may de-
pend on physical membrane properties. The N-terminal acetylation of
the protein does not seem to be important for αS's interaction with
artiﬁcial lipid membranes but maybe crucial for aggregation into
amyloid ﬁbrils [88] or be relevant for other binding partners [88].
2. αS and phospholipid membrane interactions
αS binds model phospholipid bilayers with equilibrium dissociation
constants (Kd) in the micromolar range [89]. This relatively low aﬃnity
of αS to model membranes may seem counter-intuitive as a large
fraction of the membrane binding N-terminal region of αS consists of
imperfect 11-amino acid residue repeats that resemble those found in
strongly membrane binding apolipoproteins. These repeats contain a K
(A/T)TKEGV consensus that is consistent with the capacity to fold into
an amphipathic helix [90] with a periodicity of 11 amino acids per 3
turns [91,92]. However, in contrast to what is observed for αS, the
conformational energy landscape of apolipoproteins is characterized by
a well-deﬁned energy minimum that represents the folded state. The
conformational energy landscape of IDPs such as αS is much more
continuous, this means that αS loses conformational entropy upon
binding. This loss of entropy decreases the free energy gain upon
binding and thus increases Kd. In brain tissue and cell model systems, it
is proposed that the relatively low aﬃnity of αS for membranes allows
for regulation and control over the distribution between the membrane
bound and unbound form of the protein [93,94]. The possibility to
reverse binding may for instance be important in regulating the lipid
vesicle pool at the synapse [84,95,96]. Förster resonance energy
transfer (FRET) studies indicate that there is a clear diﬀerence in con-
formation between cytosolic and membrane bound αS [97]. From ex-
periments on brain homogenates, it was estimated that approximately
15% of αS in brain is associated with membranes [98,99]. This mem-
brane associated αS is visible as distinct high-intensity puncta in
ﬂuorescence microscopy images [97]. The high intensity puncta re-
present αS bound to small vesicles. Photobleaching studies on αS-GFP
expressing diﬀerentiated SH-SY5Y cells show that approximately 70 αS
molecules are associated with each vesicle [100]. The number of αS per
vesicle is high enough for a direct role in curvature generation and
membrane remodeling [101,102]. However, this number is also strik-
ingly similar to the number of synaptobrevins, a putative interaction
partner of αS, per vesicle [103]. This suggests that membrane bound αS
has a dual role, it may both directly contribute to generating curvature
and act as a non-classical chaperone for SNARE-complex assembly [87].
Association of the unstructured monomeric αS with model phos-
pholipid membranes is accompanied by a dramatic increase in the he-
lical content of the protein from 3% to ~80% [90]. In a seminal report
by Eliezer and colleagues in 2001, membrane bound-αS was shown to
assume a bipartite structure with residues 1–102 bound to SDS micelles
while the remaining residues stay disordered [104]. The amphipathic
helix of membrane bound αS is oriented parallel to the membrane
surface. The conformation of the membrane-bound helical segment of
αS has been a matter of debate as to whether it is a fully extended helix
[91,105,106], a broken helix [107,108] or co-existence of both as
shown in vitro [109] and in vivo [97]. It seems that all these helical
architectures are possible, probably due to variable positions of the
break in the helix [105]. The distribution of αS over the extended and
broken helix conformations may depend on the lipid composition of the
membrane. Besides the lipid composition, the surface concentration of
the protein seems to have an eﬀect on the conformation. It has been
shown by NMR that αS binds to lipid bilayers via distinct binding modes
[110] that can be tuned by changing the lipid-to-protein ratio. Nu-
cleation of αS aggregation may be assisted by membranes that bind the
monomeric form of the protein. The critical aggregation concentration
of αS in solution has been reported to be ~10–30 μM [111,112]. In the
presence of negatively charged lipid bilayers aggregation is however
Fig. 2. Sequence encoded physicochemical proper-
ties of αS. A) Primary amino acid sequence with
acidic (green), lysine (red) and aromatic (light blue)
residues highlighted. B) Schematic representation of
the main (functional) regions of αS. The amphipathic
repeats housed in the membrane binding region are
indicated in red, the Non-Amyloid β Component
(NAC) region in blue and the acidic region in green.
The right panel shows a pictorial representation of a
disordered conformation of the protein.
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observed at much lower concentrations, far below the concentrations
reported for αS in cells [113–115].
2.1. Physicochemical properties of lipids aiding αS membrane interaction
There is now strong evidence that the equilibrium dissociation
constant and thus the population of the membrane-bound state of αS is
not only aﬀected by the sequence encoded (structural) properties of αS
but also by the physicochemical properties of the phospholipid bilayer,
such as anionic charge density, curvature and packing defects, phase
state and degree of hydration [90,107,116–118] [119]. Below we will
address how the binding of αS monomers, oligomers and ﬁbrils is af-
fected by physicochemical membrane properties. In reviewing the in-
teraction of oligomers with lipid bilayers we will focus on oligomers
prepared in simple buﬀer solutions in the absence of additives. For
these types of oligomers, the relation between oligomer interactions
and the physicochemical membrane properties of membranes is rela-
tively well characterized.
2.1.1. Membrane charge
2.1.1.1. Monomers. Although net negatively charged, monomeric αS
binds membranes of anionic phospholipids with much higher aﬃnity
than membranes composed of zwitterionic ones [89,120]. The
preferential binding of αS to negatively charged membranes in
comparison to net neutral membranes is attributed to attractive
electrostatic interactions between the membrane surface and multiple
positively charged lysine residues found in the N-terminal region of αS
[121]. In the membrane bound conformation, these lysines are lined up
at the boundary between the hydrophobic and hydrophilic part of the
amphipathic helix. The higher aﬃnity for negatively charged
membranes thus likely originates from the free energy gain resulting
from both helix insertion and attractive electrostatic interactions. The
involvement of attractive electrostatic interactions between αS and
negatively charged membranes is corroborated by studies showing
reduced αS binding to anionic lipid vesicles with increasing ionic
strength [122]. The increased ionic strength not only screens the
membrane charge but also changes the conformational space probed
by the protein. The changes in preferred protein conformations with
ionic strength are a possible cause for the reduced binding aﬃnity. The
binding of monomers seems to be very sensitive to the membrane
surface charge density. The binding of αS to bilayers of phosphatidic
acid (PA) and phosphatidylinositol(PI)from bovine liver lipids that have
a slightly higher negative charge at neutral pH, is high compared to
binding to bilayers of phosphatidylserine (PS) and phosphatidylglycerol
(PG) [89,118,122,123]. For membranes composed of mixtures of
zwitterionic- and anionic phospholipid the aﬃnity for αS decreases
with increasing fraction of zwitterionic lipids [89,120].
2.1.1.2. Oligomers. Like monomers, the binding of αS oligomers to
membranes depends strongly on the presence of negatively charged
lipids. The accumulated data from several experiments indicates that
for binding to occur to giant unilamellar vesicle (GUV) or large
unilamellar vesicle (LUV) membranes at least 20% of the lipids in the
membrane must carry a net negative charge [58,124,125]. The ability
of the negatively charged oligomers to speciﬁcally bind net negatively
charged lipid bilayers suggests that, like observed for monomers,
oligomer binding is mediated by the lysine residues that reside at the
membrane interface when the N-terminal region of the protein is
organized into an amphipathic α-helix. The organization of the N-
terminal residues of (part of the) monomers in the oligomers into
membrane bound amphipathic helices is supported by several
experimental ﬁndings. In the presence of small unilamellar vesicles
(SUVs), the helical content of αS oligomers has been observed to
increase [126,127]. Tryptophan ﬂuorescence experiments on single
tryptophan mutants of αS indicate that upon membrane binding the
environment experienced by residues in the N-terminal region of the
protein becomes more hydrophobic [61]. Studies on N-terminal
deletion mutants also point at the importance of the N-terminal
region of αS for the binding of αS oligomers to membranes [63].
Membrane leakage experiments indicate that, as expected for the
binding of negatively charged oligomers to negatively charged
membranes, oligomer binding is facilitated at higher ionic strengths
[59].
2.1.1.3. Fibrils. Part of the membrane binding N-terminal region of αS
remains unstructured and solvent exposed when the protein is
organized in amyloid ﬁbrils. Both in vitro and in vivo experiments
suggest that this N-terminal region of αS might retain its membrane
binding properties in the ﬁbril state [59,128,129]. Solid-state nuclear
magnetic resonance (ssNMR) studies on αS ﬁbrils formed in the
presence of negatively charged phospholipid vesicles show that the
overall fold of the αS amyloid ﬁbril is not aﬀected by the presence of
anionic phospholipid vesicles. However, there are major structural
diﬀerences between the N-terminal domains of αS in ﬁbrils formed in
the absence or presence of vesicles [130,131]. The ability of ﬁbrils to
bind vesicle membranes may however depend on the assembly
mechanism and the associated diﬀerences in ﬁbril polymorphs that
are formed. The interaction of pre-formed ﬁbrils with phospholipid
vesicles seems to diﬀer from the interaction of ﬁbrils that were
assembled in the presence of liposomes.In vitro studies indicate that
pre-formed αS amyloid ﬁbrils do not bind vesicles of the zwitterionic
lipid POPC and show only weak adherence to negatively charged
vesicles (50% POPG/50% POPC). However aggregation of αS in the
presence of the same POPG/POPC vesicles results in ﬁbrils that strongly
adhere to the membrane and deform GUVs [76]. Besides deforming
vesicles, the ﬁbrils growing on the anionic lipid bilayer surface can also
extract lipids from the bilayer resulting in protein/lipid coaggregates
[76,129,132].The lipid composition dependent interactions between αS
ﬁbrils and membranes is reﬂected in the membrane damage caused by
ﬁbrils that appear at the membrane surface. Calcein leakage
measurements show that the growth of αS ﬁbrils in the presence of
vesicles does not impair the integrity of phospholipid vesicles that have
a low aﬃnity for αS [132], while ﬁbril growth does cause dye leakage
with increasing fraction of anionic lipids in membrane [59,133]. A
recent study has shown that αS ﬁbrils can bind plasma membranes of
both neuroblastoma cell lines and hippocampal primary neurons and
induce cell death when αS monomers are additionally present [134].
2.1.2. Membrane curvature
2.1.2.1. Monomers. Membrane binding of αS involves a conformational
transition from a disordered state to an amphipathic α-helix and the
insertion of this helix into the lipid bilayer. Binding of αS to membranes
therefore depends on membrane tension and the presence of packing
defects [90]. The sensitivity to the presence of packing defects is
probably responsible for the curvature sensitivity of αS binding. αS has
been observed to bind SUVs with much higher aﬃnity than larger
vesicles. Moreover, whereas αS does not bind LUVs and GUVs of
zwitterionic lipids it does bind SUVs of zwitterionic phospholipids [88].
In SUVs with a diameter of 25–40 nm the vesicle diameter starts to
approach the lipid bilayer thickness which results in an imperfect
packing of lipids and the formation of membrane defects. These packing
defects become even more pronounced when the membrane of these
SUVs is in the liquid-ordered or gel phase.The exposed hydrophobic
surface at defects is probably responsible for the observed higher
binding aﬃnity of SUVs compared to LUVs and GUVs.Similarly,
increasing the fraction of inverted cone-shaped lipids with packing
parameter2 P > 1, like phosphatidylethanolamine (PE) in anionic lipid
vesicles enhances binding of αS [59,122].
2 Packing parameter, P=V/a*l, where V is the hydrocarbon volume, a is the
area of the head group, and l is the length of the hydrocarbon chain)
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Interestingly, αS not only binds preferentially to curved lipid
membranes but has also been shown to induce curvature and cause
remodeling of lipid membranes [102,135]. The binding of αS has been
shown to convert multilamellar vesicles and GUVs but not SUVs of
physiologically relevant phospholipid compositions into tubules and
smaller vesicles [101]. Separate studies showed that membrane re-
modeling of supported lipid bilayers by αS strongly decreases with in-
creasing anionic lipid content [136]. The membrane remodeling eﬀect
observed in these studies is likely a result of the partial insertion of an
amphipathic helix in the outer layer of the membrane [101], although
the steric pressure exerted by the solvent exposed C-terminal regions of
the protein may also contribute at high surface densities [100,137,138].
Considering the weak binding of monomeric αS the observed increase
in the tubulation of zwitterionic supported lipid bilayers is puzzling
[136].
2.1.2.2. Oligomers. Although the binding of αS oligomers to SUV, LUV
and GUV membranes was not directly compared in a single series,
binding seems to depend on curvature. Oligomers have been reported to
bind DOPC SUVs but not POPC GUVs [124,139]. This may however not
result from the ability of oligomers to sense curvature. The inability of
αS oligomers to bind POPE SUVs [124,139] suggests that binding to
SUVs of zwitterionic lipid bilayers results from packing defects and
depends on the exposure of hydrophobic surface. In some, but not all
cases the binding of oligomers results in impaired membrane integrity.
Whereas αS oligomer binding requires the presence of negatively
charged phospholipids, disruption of the lipid bilayer depends on the
accessibility of the bilayer hydrocarbon core [59]. This accessibility of
the hydrocarbon core cannot only be modulated by changing the
membrane curvature and creating packing defects, it also depends on
the packing parameters of the lipids in the bilayer.In a series with
increasing acyl chain unsaturation; POPG, DOPG, 18:2 PG, the packing
parameter P increases and lower oligomer concentrations are required
for calcein to leak out of vesicles composed of these lipids. The addition
of the more cone shaped (P < 1) lysolipids improves the packing of
lipids in the bilayer and decreases the vulnerability of the membrane to
oligomer binding induced impairment of membrane integrity [59]. The
addition of cholesterol also improves the packing of the lipid bilayer
and has a similar eﬀect [59,139]. In general, it has been observed that
although lipid bilayers of more complex physiologically relevant
membrane compositions bind oligomers, such membranes are less
vulnerable to binding induced leakage of vesicle content. The dye
release caused by αS oligomer binding from vesicles of brain extract
[139,140], or vesicles mimicking the composition of the plasma
membrane or mitochondrial membrane [127], is low compared to the
release from vesicles containing only negatively charged lipids. There
are however diﬀerences, SUVs mimicking the composition of the inner
mitochondrial membrane were more susceptible to permeabilization by
αS oligomers than model plasma membranes [127,141].Whereas the
main acidic phospholipid in the plasma membrane is the
phosphatidylserine, the inner mitochondrial membrane is enriched in
cardiolipin; a diphosphatidylglycerol carrying two negative charges.
The sensitivity of oligomer binding to membrane composition and
charge density may make the membranes of speciﬁc organelles more
vulnerable to oligomer induced damage than others [142,143].
2.1.2.3. Fibrils. To the best of our knowledge, membrane curvature
dependence of αS ﬁbril binding has not been investigated yet. However
it has been shown that when monomeric αS is aggregatedin presence of
membranes, membrane bound ﬁbrils can deform both SUVs [129]
andGUVs [76].
2.1.3. Membrane phase state
2.1.3.1. Monomers. Studies on permeabilized cells from rat brains
suggest that αS is associated with lipid rafts in the cellular membrane
[144]. These lipid rafts are deﬁned by their resistance against treatment
with anionic detergent and are typically enriched in cholesterol,
sphingolipids and speciﬁc phospholipids. In membrane model
systems, these rafts are often mimicked using binary or tertiary lipid
mixtures containing phase separated liquid ordered (Lo) domains. In
contrast to what has been observed in cellular membranes, αS typically
binds the anionic lipids in the liquid disordered (Ld) instead of the Lo
phase in these phase-separated systems [120]. However, it is important
to keep in mind that there is no direct evidence that the lipid rafts in
cells are Lo phases. Cellular membranes are not equilibrium structures
and raft formation may result from various internal driving forces
rather than from phase separation as discussed in [145].
The aﬃnity for diﬀerent membrane phase states has been studied in
more detail in simpler membrane model systems. The phase state of
membranes e.g. Lo, Ld, or gel state, depends on lipid composition and
temperature. For anionic membranes, the binding aﬃnity of αS is
higher for SUV membranes with lipids in the ﬂuid phase than for
membranes in the gel phase [146]. For SUVs and LUVs composed of
zwitterionic lipids the eﬀect is reversed, αS dissociates from these ve-
sicles upon the phase transition to the Lo state [89]. The phase transi-
tion temperature and therefore binding of αS depends strongly on the
length of and degree of saturation in the acyl chain of the lipids.
However, also above the Lo to Ld transition temperature the binding of
αS is aﬀected by the degree of saturation in the acyl chains of the lipids
in the bilayer. Compared to membranes composed of saturated lipids,
binding of αS to membranes of unsaturated lipids of the same length is
higher [89,120]. The sensitivity of αS binding to the membrane com-
position and phase state of membranes of zwitterionic lipids indicates
that exposed hydrophobic area enhances binding. Defects in mem-
branes below the phase transition temperature and the less tight
packing of unsaturated compared to saturated lipids in membranes
above the phase transition temperature reduce the screening of the
apolar acyl chains in the bilayer. Membrane defects and decreased lipid
packing thus both enhance the insertion of the amphipathic helix of αS
into the bilayer.
It is important to realize that the phase state and lipid packing not
only aﬀect binding of αS but that binding also changes these parameters
[107,116,147]. EPR and ﬂuorescence spectroscopy show that binding
of αS to SUVs of zwitterionic lipids led to an increased chain melting
temperatures and to enhanced cooperativity of the phase transition
[148]. By contrast, CD and DSC results suggest that αS binding stabi-
lizes the ﬂuid phase of bilayers of negatively charged lipids. Experi-
ments from our own lab indicate that αS organizes in clusters at pro-
tein:lipid ratios higher than 10 [113]. At such higher ratios, all αS
binding sites on the membrane surface are occupied, the average dis-
tance between two membrane-bound monomers is small and inter-
protein collisions result in cluster formation. Clustering of membrane-
bound αS at high surface concentration is a consequence of a complex
interplay mainly between attractive hydrophobic interactions, resulting
from the solvent exposed hydrophobic patches on the membrane-bound
αS, and repulsive electrostatic interactions, resulting from the nega-
tively charged unstructured solvent exposed C-terminal region of αS.
The correlation between the changes in lipid diﬀusion and DPH ani-
sotropy, suggests a concerted process where the formation of clusters
leads to a closer packing of lipids and a decrease of the eﬀective lipid
diﬀusion [149]. The relation between the eﬀective lipid diﬀusion and
area of the αS clusters (Fig. 3) is nontrivial as it does not result from a
direct interaction between proteins and lipids. Although aS mainly
binds to anionic lipids, clustering also aﬀects eﬀective lipid diﬀusion of
zwitterionic lipids. This indicates that the clustering of αS on lipid
membranes induces ordering of underlying lipids. In the Ld membranes
studied, we observed an overall increased lipid packing order with in-
creasing size of the lipid clusters (Fig. 3).
For membranes in the Lo state, the opposite has been reported; αS
decreases the packing order in lipid mixtures that form Lo membranes
[51]. Cholesterol aﬀects the packing order in lipid membranes in a si-
milar way; it increases the packing of membranes in the Ld state and
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makes membranes in the Lo state more ﬂuid. Clustering of proteins and
ordering of lipids into membrane microdomains are both known to be
involved in protein function and this interplay forms the basis for many
cellular signaling processes [145]. The aforementioned studies on αS
suggest, albeit from in vitro observations, that αS may play a role in the
regulation of lipid packing in cell membranes.
2.1.3.2. Oligomers. Preferential binding of αS oligomers to membranes
in the Lo over the Ld state was studied in GUV membranes with
coexisting Ld and Lo domains. In these experiments oligomers
preferentially accumulated in the Ld domains [124]. Additionally,
vesicles of anionic lipids in the L0 state were not able to bind
oligomers [124]. The close packing of lipids in the Lo state probably
interferes with the insertion of the amphipathic helix even when the
surface charge is high enough. Considering the sensitivity of αS
oligomer binding to packing defects, one could imagine that αS
oligomers preferentially accumulate at the interface between the Lo
and Ld state. There are however no indications that is the case.
2.1.3.3. Fibrils. To the best of our knowledge, the binding of preformed
ﬁbrils to vesicles with membranes in diﬀerent membrane phase states
has not been investigated yet. However, when ﬁbrils were formed in the
presence of net negatively charged SUVs or GUVs large scale vesicle
deformations were observed [76,129]. Fibrils at the membrane surface
cause the initially spherical GUVs to become faceted. This faceting may
indicate that the binding of ﬁbrils causes the membrane to become
more rigid or to develop rigid domains. However, dye leakage studies
and the distribution of dyes which preferentially accumulate in Ld over
Lo domains indicated that the tight coupling to a mesh work of ﬁbrils,
rather than a rigidiﬁcation of the membrane, is the more likely cause of
the observed vesicle shape changes [76].
The aggregation of αS on or in the presence of membranes seems to
be aﬀected by the membrane composition. Despite the fact that
monomeric αS binds with similar aﬃnities to model membranes com-
posed of diﬀerent negatively charged phospholipids, it was shown
recently that the aggregation of the protein is enhanced only in the
presence of membranes composed of lipids with the shortest hydro-
carbon chains (Fig. 4) and hence highest solubility [146,150]. Mem-
branes composed of phospholipids with 16 or 18 carbons in each acyl
chain including DOPE, DOPC, DOPS, POPS do bind αS but do not en-
hance the aggregation of the protein when incubated for several days
under quiescent conditions [146]. Experiments in which αS aggregation
was followed in the presence of LUVs composed of POPG:POPC (1:1),
POPG:POPE:POPI (11:3:6), or POPC/POPE/Cardiolipin (5:3:4) also
showed no enhanced αS aggregation [132]. The standard change in free
energy of transfer of a lipid molecule from water into a bilayer, and thus
the solubility, correlates strongly with the length of its lipid hydro-
carbon chain(s) [151] (Fig. 4). Lipids with the highest solubility in
aqueous solutions triggered αS aggregation. This is in good agreement
with earlier experiments were αS aggregation was followed in the
presence of SDS below and above the critical micelle concentration
[152]. Below the CMC, the ﬁbril formation process was concluded to be
mediated by the formation of micelle like clusters at the surface of αS
molecules. Above the CMC, the presence of SDS micelles inhibited ﬁbril
formation, probably because the presence of micelles decreases the
concentration of free/unbound αS in solution. In summary, the high
solubility of single chain surfactants and (charged) phospholipids with
short acyl chains results in a considerable concentration of these am-
phiphiles in solution. These solubilized lipids and surfactants interact
with αS and induce its aggregation. The ability of vesicles to increase
the aggregation rate and decrease the aggregation lag time thus de-
pends on lipid solubility rather than membrane phase state.
Although αS aggregation is not accelerated in the presence of ve-
sicles of less soluble phospholipids, the low solubility of these lipids
cannot prevent lipid extraction when membrane bound αS is in-
corporated in ﬁbrils [132]. Aggregation of membrane bound αS has
been reported to result in extraction of lipids and the appearance of
protein/lipid co-aggregates [76,115,129,132,153]. This lipid extraction
can consume the complete vesicle bilayer and is therefore disruptive.
Fig. 3. Master curve of data correlating changes in lipid diﬀusion (black solid
symbols) and lipid packing (blue open symbols) measured as the absolute
steady-state anisotropy values of DPH in liposomes to membrane-bound αS
cluster areas. Relative changes in the lipid diﬀusion coeﬃcients are plotted
against mean αS cluster areas. WT-αS is depicted as squares whereas the
Δ71–82-αS variant is shown as circles. The 1–108-αS variant (downward tri-
angles) results in the biggest change in lipid diﬀusion coeﬃcients and DPH
anisotropy followed by the 1–60-αS variant (upward triangles). The dotted lines
are representative of the general trend in increasing anisotropy (blue lines) and
changes in lipid diﬀusion (black lines). (Figure and legend reused with per-
mission from [149].)
Fig. 4. Physicochemical properties of lipids inﬂuence the binding stoichiometry
and the aggregation propensity of αS in the presence of model membranes. The
energy gained by transferring a lipid molecule from the water phase into the
bilayer (ΔG°tr, 30 °C) (orange), the stoichiometry of αS:lipid binding in the
bound state (blue), and the half-time for the aggregation of αS (black) are
plotted for each lipid system: DLPS [(12:0)2], DMPS [(14:0)2], DPPS [(16:0)2],
POPS (16:0/18:1), and DOPS [(18:1)2]. The phase of each lipid systems in the
presence of an excess of protein at 30 °C is indicated below the x axis. (Figure
reused with permission from [146].) (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this
article.)
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In summary, it seems that the interactions of αS monomers, oligo-
mers and ﬁbrils with phospholipid membranes respond similarly to the
membrane's physicochemical properties. Besides the physicochemical
properties of membranes discussed above, interactions between αS and
membranes are also inﬂuenced by the chemical composition of the
membranes and the presence of speciﬁc lipids. How the chemical
composition of membranes aﬀects the aggregation of αS has recently
been reviewed by [153] and will not be addressed here.
Most of the investigations on the relation between the physico-
chemical properties of membranes and the interactions with diﬀerent
αS species have been performed on the non-acetylated version of αS
while in vivo most αS contain this post-translational modiﬁcation. Do
monomeric, oligomeric and ﬁbrillar N-terminally acetylated αS species
respond diﬀerently to changes in membrane properties? Will N-term-
inal acetylation of αS proteins containing one of the familial PD sub-
stitutions change our view on αS-membrane interactions and αS
mediated pathology in PD? Addressing these questions may bring us a
step closer to understanding the role of αS-membrane interactions in
PD.
2.2. Post-translational modiﬁcations and mutations in αS inﬂuencing
membrane interactions
In vivo, both the monomeric and ﬁbrillar form of αS have been
observed to be post-translationally modiﬁed. The reported post-trans-
lational modiﬁcations (PTMs) include acetylation [34,79,88,154],
phosphorylation [34,155–157], methionine oxidation [158], nitration
[159], ubiquitination [34,160], SUMOylation [161] and truncations.
The relevance of PTMs for αS function and the role of PTMs in the
etiology of PD are not clear yet. Considering that several of the PTMs
aﬀect the net charge or charge distribution on the protein, PTMs change
the aggregation propensity and may inﬂuence the distribution of the
monomeric protein over (functional) conformational sub-ensembles.
Post-translational modiﬁcations may thus directly or indirectly impact
αS interactions with lipid membranes. PTMs can thus either have a
regulative eﬀect on cell physiology for functional purposes or be dis-
ruptive to the existing function of αS leading to PD pathology. The
consequences of these PTMs for the interaction of αS with membranes
will be discussed in this section.
2.2.1. N-terminal acetylation
The main functional PTM found in human αS is N-terminal acet-
ylation [34,79,154,162,164]. How this acetylation aﬀects the αS
membrane binding ability has been under debate. Initially conﬂicting
results were reported; N-terminal acetylation was observed to enhance
membrane binding in some studies while a negligible impact of the
PTM was reported by others [154,162]. Recent investigations have
shown that N-terminal acetylation enhances binding to SUVs containing
no or a low percentage of negatively charged phospholipids. For
membranes with higher surface charge densities the eﬀect of the PTM
on binding was much less pronounced [88,163]. Considering the im-
portance of the positively charged amino acid residues in the N-term-
inal region of αS for binding to anionic phospholipid bilayers the loss of
a positive charge upon acetylation is expected to decrease the aﬃnity
for anionic lipid bilayers. However, N-terminal acetylation increases
the propensity of the ﬁrst 14 residues of the protein to organize into
helices. The helical content of the N-terminally acetylated protein in
buﬀer is considerably higher than that of the unmodiﬁed protein [162].
Thus, the loss in conformational entropy upon binding to anionic
phospholipid membranes is probably lower for N-terminally acetylated
αS than that for the unstructured unmodiﬁed αS. The loss of the posi-
tively N-terminal residue upon acetylation is balanced by the lower
entropy cost associated with helix formation. Binding of unmodiﬁed
and N-terminally acetylated αS to negatively charged lipid bilayers is
therefore comparable. Since binding of αS to bilayers of zwitterionic
lipids does not strongly rely on attraction between oppositely charged
surfaces, the eﬀect of N-terminal acetylation is dominated by the in-
creased propensity of the protein to fold into an amphipathic he-
lix.Because the ﬁnal helical content of both membrane-bound proteins
is comparable, the net free energy gain upon binding of unmodiﬁed αS
to membranes of zwitterionic lipids is lower resulting in a measurable
increase in aﬃnity for N-terminally acetylated αS compared to un-
modiﬁed αS [88].
2.2.2. Phosphorylation
Whereas N-terminal acetylation is functional, phosphorylation of αS
is associated with disease conditions. According to early reports ap-
proximately 90% of αS in LBs is phosphorylated at Ser129 (pS129)
[164] whereas only a small proportion (< 5%) of the monomeric
protein contained this PTM. Later studies indicated that besides pS129,
phosphorylated Ser87 can be considered a pathological hallmark of αS
inclusions [165]. Based on the presence of phosphorylated protein in
LBs, it was hypothesized that phosphorylation of αS promotes ag-
gregation in vivo. Subsequent in vitro studies conﬁrmed this; phos-
phorylation of αS at residues S87 and Ser129 was observed to induce
the formation of relatively extended conformations exposing the ag-
gregation prone NAC region and increasing the aggregation propensity
[165–168]. However, other in vitro aggregation assays could not con-
ﬁrm the hypothesis that phosphorylation promotes aggregation [169].
Phosphorylation of S87 reduces the binding aﬃnity to lipid mem-
branes [155,170] and alters the detergent micelle bound conformation
[165]. In vitro experiments probing the binding aﬃnity of pS129 to
phospholipid membranes have, like the aggregation studies, not been
able to generate a uniﬁed view. Some studies report that phosphor-
ylation at S129 does not change the aﬃnity of αS for membranes and
that it only moderately enhances binding of PD-linked mutations of αS
(A53T and A30P) [35,164]. Others report a reduction of the membrane
binding aﬃnity for αS phosphorylated by a G protein-coupled receptor
kinase (GRK) [171,172]. The apparent discrepancy in the eﬀect of
phosphorylation on membrane binding could be a result of diﬀerent
kinases used in these experiments; creatine kinase (CK1) and Pollo-like
kinase (PLK2) in the ﬁrst study versus GRK in the latter, as reviewed
extensively in [169]. These diﬀerent kinases will most likely diﬀerently
phosphorylate other residues besides S129. Like observed for GRK
phosphorylated αS, the binding aﬃnity of the phosphomimic S129E to
membranes was lower than that of the unmodiﬁed protein [171,172].
Phosphomimics have generated relatively reproducible data in cellular
and animal studies probing the inﬂuence of phosphorylation of αS. The
αS-membrane interaction was shown to be inhibited by this phos-
phorylation mimicking αS mutation in yeast and worm models of PD.
The mutation of αS to the unphophorylatable S129A variant increases
the fraction of membrane-bound αS, while the mutation to the S129D
phosphomimic decreases the fraction of membrane-bound αS
[173,174]. In an adeno-associated virus (AAV)-based rat genetic model
of PD, immuno-electron microscopy images showed that the majority of
αS associated with cellular membranes was S129A [175]. However, the
phospho-mimics (S129D/E) do not replicate the exact properties of
physiologically phosphorylated αS [35,176]. The structural and func-
tional consequences of phosphorylation on lipid membrane binding
remain therefore incompletely understood.
2.2.3. Oxidative modiﬁcations: tyrosine nitration and methionine oxidation
Their oxygen consumption rate makes dopaminergic neurons quite
susceptible to oxidative stress [177]. Under conditions of oxidative
stress all four tyrosines in αS (Fig. 5) can be nitrated in vitro and this
nitration has also been observed in LBs from the brains of PD patients
[159,178–180]. In vitro nitration of Tyr-39 or the C-terminal tyrosines
leads to a decreased binding of αS to membranes composed of anionic
lipids [181]. The sensitivity of membrane binding to C-terminal nitra-
tion is interesting; the C-terminus is not thought to interact directly
with membranes. The sensitivity of αS-membrane interactions to ni-
tration suggests a long-range allosteric communication between the C-
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terminal and the membrane binding regions. Other oxidative PTMs that
possibly inﬂuence membrane binding of αS include methionine oxida-
tion [158,182] but the eﬀects of methionine oxidation on membrane
binding is not investigated yet.
2.2.3.1. Truncation. Up to 15% of the αS in LBs contains N-terminal
and C-terminal truncations [183,184]. In vitro experiments have shown
truncations can have a large eﬀect on amyloid ﬁbril structure and
morphology [185]. However, these PTMs of αS are also commonly
found in healthy brain tissue and in cultured cells [186–188].Thus, αS
truncation does not per se result in disease. The N-terminal region of αS
with its imperfect KTKEGV repeat motifs is important for establishing
membrane interactions. Truncations of the N-terminal region are
therefore expected to negatively aﬀect the membrane binding aﬃnity
of αS. The high number of negatively charged amino acids in the C-
terminal region may modulate interactions with negatively charged
membranes but compared to truncations in the N-terminal region, they
are expected to have less eﬀect on membrane binding. Initial studies
reported that deletion of the ﬁrst 10 N-terminal amino acids (residues
2–11) dramatically reduced binding to vesicles and yeast membranes
[189]. Concomitant with the lower binding aﬃnity, the overexpression
of this deletion mutant was observed to be considerable less toxic than
overexpression of the full-length protein. However, although less toxic
in yeast, a subsequent study by the same group failed to reproduce the
reduced membrane binding and toxicity in human neuroblastoma
SHSY-5Y cells [190]. Diﬀerences in lipid composition, membrane
ﬂuidity and cytosolic factors between yeast and SH-SY5Y cells likely
cause this apparent disparity. The observed diﬀerences thus indicate
that the choice of the model system is critical.
In vitro studies show that the amino acids 1–25 in the N-terminal
region of αS trigger membrane binding and helix folding [191]. How-
ever, the peptide 1–20 had extremely low aﬃnity for anionic liposomes
compared to 1–25 and full-length αS. The low aﬃnity of the 1–20
peptide was attributed to the net zero charge of the peptide. However,
experiments with other truncations variants show that a net positive
charge is not suﬃcient for membrane recognition and helix folding.
Instead the N-terminal residues impart some kind of conformational
selectivity that allows for membrane recognition [191].
More recent studies have conﬁrmed the roles of the N- and C-ter-
minus in membrane binding. Using a small peptide tagged αS (αS-myc),
it was shown that truncations in the unstructured C-terminus of αS have
minimal eﬀect on lipid binding in vitro and do not aﬀect the presynaptic
localization of αS in cultured cortical mouse neurons [192]. The C-
terminus, however is essential for synaptobrevin-2 binding and pro-
moting SNARE-complex assembly [192]. N-terminal truncations in αS,
as expected, decreased membrane binding aﬃnity to artiﬁcial lipid
membranes and signiﬁcantly decreased the presynaptic localization of
αS in cultured cortical mouse neurons [192]. In general, the behavior of
N- and C-terminal truncation variants to membrane binding are com-
parable in vitro and in vivo.
2.2.3.2. SUMOylation. SUMOylation is a post-translational
modiﬁcation that involves the enzymatic addition of small ubiquitin-
related modiﬁer (SUMO) to proteins [193]. SUMOylation of αS has
been shown to occur in HEK293 cells [161] and transgenic mice [194].
SUMOylation is thought to regulate protein-protein and protein-DNA
interactions, it additionally promotes protein solubility [195,196].
SUMOylation has been observed on several lysine residues in αS, the
most signiﬁcant of which are lysines 96 and 102. Although the sorting
of αS in extracellular vesicles is regulated by SUMOylation and
membrane interactions may thus be important it remains to be
investigated if in vivo or in vitro membrane binding of αS is
inﬂuenced by SUMOylation [197].
2.2.3.3. Point mutations. All known familial PD point mutations
resulting in single amino acid substitutions in αS (A30P, A53T,
H50Q, G51D and E46K) reside in its membrane binding region
(residues 1–60). Compared to unmodiﬁed αS, these single amino acid
substitutions either promote or impede membrane-associations of αS
[110,118,198–200]. Like observed for unmodiﬁed αS, the membrane
binding aﬃnities of the disease mutants increase with the fraction of
negatively charged lipids in the membrane [199,200] or the presence of
packing defects in small-sized vesicles [118].
Compared to unmodiﬁed αS, A30P shows a reduced binding aﬃnity
to artiﬁcial lipid membranes. This reduced aﬃnity presumably results
from the break in the membrane bound amphipathic helix caused by
the presence of a Pro residue [110,118,198,201,202]. In accordance
with this hypothesis, mutations of conserved residues in the membrane
binding part of αS to prolines resulted in proteins with a reduced
membrane binding aﬃnity, with the exception of G41P [192]. For the
PD related E46K mutation in αS, an increased aﬃnity for binding
phospholipid bilayers is observed which can be attributedto enhanced
attractive electrostatic interactions resulting from the presence of an
additional Lys residue [110,118,198,201]. There is currently some
Fig. 5. Overview of post-translational modiﬁcations in αS.
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inconsistency regarding data reported on the binding aﬃnity of the
A53T mutant to artiﬁcial lipid membranes. Compared with unmodiﬁed
αS, A53T showed either reduced [199,203] or similar [110,198,201]
binding aﬃnities. The H50Q and G51D mutations have not yet been
extensively studied. Compared to unmodiﬁed αS, the G51D mutation
decreases the membrane binding aﬃnity, but promotes the formation
of partly helical states [204], while the H50Q mutation does not alter
binding aﬃnity orthe fold of the bound-state signiﬁcantly [205].
Unmodiﬁed αS and disease related mutants bind to artiﬁcial lipid
membranes using a very similar combination of electrostatic and hy-
drophobic interactions [118,199,200], but the presence of vesicles
diﬀerently aﬀects their aggregation into amyloid ﬁbrils. In a study
performed in the presence of exosomes derived from mouse neuro-
blastoma cells the ﬁbrillation rates were observed to decrease in the
order A53T > A30P > E46K > unmodiﬁed αS [206].
So far, all the PTMs in αS have been investigated separately, studies
aimed at probing the combined eﬀects of diﬀerent coexisting PTMs are
still lacking. For example, phosphorylation at Y125, ubiquitination at
K96 or K102 or C-terminal truncations co-exist with pS129, although
the modiﬁcation sequence is unknown. Although PTMs in αS occur at
multiple sites, certain positions can carry diﬀerent modiﬁcations
(Fig. 5). The functional/pathogenic consequences of combinations of
PTMs also require further investigations.
3. The Janus face of αS
To explain the role of the conformational transition of αS from its
disordered state to the oligomeric and ﬁbrillar states in PD etiology,
several mechanisms of αS mediated cellular toxicity and death have
been postulated. These mechanisms can be grouped into two major
classes: they either assume a gain of toxic function or a toxic loss of
function. Both gain and loss of function mechanisms result in failure of
the ubiquitin-proteasome system (UPS), oxidative stress, impaired ax-
onal transport and mitochondrial damage [28,98,207–215]. Although
not established, gain and loss of function mechanisms may not be
mutually exclusive and possibly act synergistically. The interaction
between diﬀerent cellular processes, makes it diﬃcult to pinpoint one
single intracellular location or pathway that is aﬀected in the early
stages of PD and eventually results in neuronal cell death. Possibly
many diﬀerent pathways contribute to cell death in PD.
In current literature, the roles attributed to αS in PD come in op-
posites, in this respect the protein seems to resemble the mythological
two-faced Roman god Janus. On one hand, in both familial/idiopathic
cases of PD [28,74], the failure of cellular processes stems from αS
point mutations and the overexpression and aggregation of αS into
toxic pre-ﬁbrillar, oligomeric and/or ﬁbrillar species [66,68]. In this
respect, soluble oligomeric species of αS have been argued to be the
most potent toxic species in both in vitro and in vivo systems
[53,216–219]. However, the observed transmission of the amyloid fold
from one cell to another suggests a critical role for ﬁbrils [220]. When
particle instead of equivalent monomer concentrations are compared
ﬁbrils seem more toxic than oligomers [139].The toxicity of ﬁbrils
seems to depend on the ﬁbril strain [74] and the toxicity of LB for-
mations on the cellular compartment in which ﬁbrils accumulate
[221].On the other hand, a number of reports suggest that over-
expression of αS per se and aggregation into soluble oligomeric (formed
in presence of dopamine) and ﬁbrillar species has a neuroprotective
role in PD [28,213,222–224]. This neuroprotective role of αS is also
supported by the fact that PD and the associated death of dopaminergic
neurons can also occur without formation of LBs [225,226]. The neu-
roprotective role of aggregates and the absence of a clear correlation
between the number of LBs and disease raises questions about the
precise role of αS in PD. The Janus face of αS also becomes visible in the
role the protein may play during oxidative stress. The scarcity of de-
fense mechanisms against oxidative damage and a high oxygen con-
sumption rate make dopaminergic neurons susceptible to insult by
oxidative stress [177]. Oxidation of brain lipids, polyunsaturated fatty
acids (PUFAs) and dopamine in particular, can aﬀect normal func-
tioning of cell membranes. These eﬀects of oxidation increase with age
and have been linked to PD [227,228]. Several studies have suggested
that αS acts on cellular vesicles acts as an anti-oxidant; αS levels are
elevated in neurons exposed to chronic oxidative stress and such neu-
rons showed increased resistance to apoptosis [211]. The binding of
monomeric αS to the lipid bilayer prevents oxidation of unsaturated
lipids in vesicle models [229].αS has been shown to be protective by
interacting with excess dopamine and its oxidized products. In in vi-
troexperiments the interaction of αS with dopamine results in the for-
mation of non-toxic oligomeric intermediates [45,127] αSthereby pre-
vents toxic interactions of lipid molecules with excess dopamine species
[213,230]. However, the interactions of αS with dopamine are not only
beneﬁcial. Increased levels of dopamine have been shown to result in
stabilization of protoﬁbrillar species of αS that have been shown to be
toxic to cells [231] [232]. αS plays a role in the regulation of dopamine
transporters preventing dopamine accumulation in neuronal cells
[213]. Deﬁciencies in dopamine packing into vesicles in mice results in
an increase in cytosolic dopamine and a corresponding accumulation of
αS which causes death of mice dopaminergic neurons [230,233]. The
absence of αS in such mice correlated with better survival suggesting
presence of αS aggravates dopamine mediated toxicity [233]. The
Janus face of the protein may be a result of its ability to also interact
with many other cellular components besides membranes as ex-
empliﬁed by the contrasting ﬁndings on its function and cytotoxicity in
mitochondria. One of the proposed physiological functions of αS in-
volves the modulation of mitochondrial complex I activity [232,234].
By controlling activity αS prevents mitochondrial complex I induced
apoptosis. Additionally, the interaction of αS with apoptosis-promoting
proteins promotes resistance against mitochondrial toxins [235]. Lastly,
the absence of αS in mitochondria alters the mitochondrial lipid com-
position and causes a reduction in the activities of complexes I and III
[212].However, besides a protective role, the interaction of αS with
mitochondrial membranes and membrane proteins in neuronal cells has
been reported to be toxic. αS mediated mitochondrial dysfunction due
to inhibition of the respiratory chain is thought to be one of the major
triggers for both familial and age-dependent PD [236,237]. Inhibition
of mitochondrial complexes I and III results in increased oxidative stress
and the generation of reactive oxygen species. The inhibition of the
oxidative phosphorylation chain and generation of ROS has con-
sequences for active downstream processes including SNARE mediated
exocytosis [238]. Other possible mechanisms by which αS binding can
result in mitochondrial damage include the release of cytochrome c,
increase of mitochondrial calcium and concomitant apoptosis [237].
Besides cytotoxic mechanisms that involve oxidative stress, αS ag-
gregates have also been reported to induce fragmentation of mi-
tochondrial membranes [239,240]. This fragmentation of mitochondria
is often associated with the degradation of dysfunctional organelles.
4. Conclusions and future perspectives
Although the function of αS and its role in PD remain debated, the
interaction of αS species with cellular membranes seem to be important
for both function and toxicity. In this respect, the interactions with
membranes of intracellular vesicles and mitochondria seem to be most
signiﬁcant.Despite the observations that speciﬁc intracellular mem-
branes are targeted by αS aggregation or speciﬁc αS aggregates, the
molecular mechanisms underlying membrane disruption are in many
cases not well understood. The inherent compositional complexity of
biological membranes and largely unknown physiological functions of
αS impede obtaining molecular insights into the mechanisms by which
αS aggregates disrupt cellular membranes. Additionally, the impact of
relevant combinations of PTM of αS on membrane binding and ag-
gregation have been largely ignored. In spite of this, the studies on
diﬀerent model phospholipid membranes reviewed here indicate that
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the αS residues that enable functional monomer-membrane interactions
can become disruptive in αS aggregates. How combinations of struc-
tural and binding properties of speciﬁc aggregate species confer toxicity
is still a largely open question.
Membranes have not only been identiﬁed as a direct target of toxic
interactions with αS species, interactions of αS with the membrane
(lipids) also potentially play a role in the aggregation of the protein. If
and how enhanced aggregation results from crowding of protein at the
membrane surface and/or is a result of interactions with lipids in so-
lution remains to be investigated. In this respect it will be important to
carefully reevaluate both the in vitro and in vivo membrane model
systems of choice. Opposite eﬀects in membrane binding and toxicity
have been observed in diﬀerent organisms. Although diﬀerences in
interactions of αS with soluble components in these systems will play a
role at least part of this diﬀerence in membrane binding can probably
be contributed to diﬀerences in membrane composition. Diﬀerence in
membrane composition may not only aﬀect the membrane aﬃnity of
αS, in vitro studies have shown that the lipid composition aﬀects the
aggregation pathway. Diﬀerent pathways have been shown to give rise
to oligomeric, ﬁbrillar or amorphous aggregates. All of these aggregates
have been implicated in toxicity but they are thought to act via diﬀerent
mechanisms. Studies with non-abundant biological lipids or non-phy-
siological membrane compositions may give a wealth of information on
interactions and possible toxic mechanisms. However, these mechan-
isms may have little relevance in vivo. Increasing the complexity of
model membranes to more closely mimic the properties of cellular
membranes may help but a better characterization of the evolution of
membrane bound αS species in vivo is required.
Taken together, the wealth of data obtained in the last two decades
points towards a scenario wherein the interaction of αS with mem-
branes can be neuroprotective but at the same time lipid membranes
have been indicated to aid αS aggregation by creating an environment
that enhances the assembly of early aggregate species. The interaction
of αS aggregates, that form either on cell membranes or in solution,
with membranes can result in cellular dysfunction and even cell death.
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